Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-HyperCVAD Alternating With Rituximab-Methotrexate-Cytarabine in Newly Diagnosed DLBCL With MYC-Rearrangement
NCT01854372Phase 2Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Jun 2013
- Primary completion
- Nov 2013
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cyclophosphamide, doxorubicin, vincristine, dexamethasone and 2 more in diffuse large B-cell lymphoma (DLBCL) and Burkitt-like lymphoma (BLL), sponsored by UT Health San Antonio. Primary endpoint: Progression-Free Survival at 1 year. Planned start Jun 2013; status: withdrawn.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristinedexamethasone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Burkitt-like lymphoma (BLL)
Beyond the preview
Go deeper on NCT01854372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01854372.